Zageno Surpasses its Growth Targets in First Half of 2018; Adds Resources and Structures to Accelerate Growth for the Rest of the Year
New Hires Include VP, Finance Johann du Toit and VP, U.S. Sales Rafael Casiano ·Headquarters Moves to Cambridge, Mass. USA
CAMBRIDGE, Mass. USA and BERLIN, Germany, June 27, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., an online biotech marketplace, has quadrupled sales in the first half of 2018, exceeding its planned growth trajectory for the year. Chief Executive Officer David Pumberger, Ph.D., attributing success to date to the company's customer-centric culture, announces plans to accelerate growth in the second half of the year. These include: an expanded leadership team comprising key hires in critical positions, bolstered processes and operations so Zageno can extend its high level of responsiveness to an ever-growing list of customer and vendor partners, and a headquarter move to Cambridge, Massachusetts.
"It may sound trite, but we really care about our customers, and it shows," said Pumberger. "Ask them what made them try Zageno for the very first time and there's a good chance they can't tell you: 'Hmm.I saw magnets with the Zageno name everywhere? I heard about it from a friend? To tell you the truth, I can't remember.'
"But if you ask about their experience, their answer is some variation of this: 'I love Zageno's people. I use the chat function or talk to a real person on the phone. And even when I'm not particularly happy because something's not going my way - they work hard to find a quick resolution. It's always a pleasant interaction - and that's so unusual today.'"
Pumberger added, "It may seem counterintuitive for what's, in theory, a 'virtual' company, but one of the founding principles behind Zageno is that close interpersonal connection we develop with our customers to help them succeed. We are committed to building this as we grow, which is why we decided to move our headquarters to the biotech hub of Cambridge - home to many of our key stakeholders: major U.S. academic research institutions, pharma and biotech companies and vendors, and life-science startups.
"It's why we've been adding experienced scientists across the spectrum of research to our customer-service group, and why we are expanding our leadership team." The founders' hiring goal, according to Pumberger: bring in individuals with the experience, skills, and demonstrated track record the company needs so it can delight existing and new customers and vendor partners with even better product offerings and services - while positioning Zageno for accelerated growth and the company's next stage of development.
Johann du Toit and Rafael Casiano will provide the backbone of the company's enhanced administrative and commercial structure as vice presidents of finance and U.S. sales, respectively.
With increased revenues, expanded vendor contracts, and plans for securing additional capital in the company's future, Zageno is formalizing key aspects of its operations. Johann du Toit will be joining Zageno August 1st, bringing a broad range of global finance experience to his charge of building the company's finance function with a modernized approach to facilitating international payment flows, cost control, and more transparency to internal and external stakeholders. He has well-rounded leadership experience, managing projects at Ernst & Young, KPMG, and IKB Deutsche Industriebank, where his mastery of financial modeling proved to be indispensable for his clients' strategy decisions. Most recently, du Toit has taken on interim CFO roles to help several small to medium enterprises to raise funds and streamline their finance functions, among other critical tasks for companies on a rapid growth trajectory. He is a chartered accountant [CA/(SA)], and holds an executive master's in business administration (EMBA) from IE Business School, specializing in entrepreneurship, and a bachelor's degree in finance, accounting, tax, and auditing from the University of Pretoria in South Africa.
Zageno will develop repeatable sales processes under the leadership of Rafael Casiano, who joined Zageno in May. He began his career in the laboratory as a microbiologist at the Florida Department of Agriculture and subsequently led the QC lab for Pall Corporation, where he transitioned to a key account manager position and found his passion in sales and business development. For more than 20 years, Casiano approached his commercial roles successfully as a tenacious customer advocate, amassing deep relationships throughout pharmaceutical, biotechnology, and academic markets. As a global commercial leader at GE Healthcare, he developed commercial processes, combining sales and project-management disciplines to help advance cancer biomarker discovery. He holds a bachelor's degree in microbiology from the University of South Florida.
Chief Revenue Officer Florian Wegener, M.D., Ph.D., M.B.A., commented, "I'm excited to bring in new leadership who will enhance our company culture. We want customers to be able to remember their first personal interaction with Zageno and to tell their colleagues that we were right beside them when we simplified their administrative tasks, integrated into their existing processes, saving them time and money - resolving issues and needs they didn't even know they had."
Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions' procurement offices with leading life-science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising about five million products. What do we do? 1) We make purchasing transactions more efficient for both buyers and sellers. 2) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 3) We provide a valuable, expanded sales channel for our vendor partners. The growing Zageno team of 60 in Cambridge, USA, and Berlin, Germany, includes accessible experts in science, e-commerce, systems integration, and customer support. Our people work directly with customers to enable smarter, faster processes - allowing more time and resources for value-added science and better research results.
Caroline Grossman, Communications & Public Affairs, Mirepoix LLC
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire
Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CEST | Pressmeddelande
STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: email@example.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: firstname.lastname@example.org TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen
Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CEST | Pressmeddelande
STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: email@example.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: firstname.lastname@example.org TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p
Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CEST | Pressmeddelande
STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva
Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CEST | Pressmeddelande
STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre
Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CEST | Pressmeddelande
Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201
Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CEST | Pressmeddelande
Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum